Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report explains the definition, types, applications, major countries, and major players of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Salix Pharmaceuticals Ltd
GlaxoSmithKline
Astellas Pharmaceuticals
AstraZenenca
Pfizer
Actavis
By Type:
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
By End-User:
Hospitals
Clinics
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Outlook to 2028- Original Forecasts
-
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market- Recent Developments
-
6.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market News and Developments
-
6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Deals Landscape
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials and Cost Structure Analysis
-
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
-
7.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Trend of Key Raw Materials
-
7.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Suppliers of Raw Materials
-
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate of Raw Materials
-
7.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Cost Structure Analysis
-
7.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials Analysis
-
7.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Labor Cost Analysis
-
7.5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Expenses Analysis
8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Preface Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Eluxadoline Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Alosetron Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Rifaximin Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Loperamide Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Diphenoxylate + Atropine Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Dicyclomine and Hyoscyamine Consumption and Growth Rate (2017-2022)
-
9.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Outlook till 2022
-
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.2.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.2.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.2 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.3 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.4 Belgium Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.5 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.7 Denmark Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.8 Finland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.9 Norway Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.10 Sweden Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.11 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.12 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.3.13 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.4 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.8 Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.9 Singapore Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.11 Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.2 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.3 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.4 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.6 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6.3 Oman Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6.4 Qatar Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.7.2 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.7.3 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.7.4 Algeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption (2017-2022)
11 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis
-
11.1 Salix Pharmaceuticals Ltd
-
11.1.1 Salix Pharmaceuticals Ltd Company Details
-
11.1.2 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.1.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 GlaxoSmithKline
-
11.2.1 GlaxoSmithKline Company Details
-
11.2.2 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.2.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Astellas Pharmaceuticals
-
11.3.1 Astellas Pharmaceuticals Company Details
-
11.3.2 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 AstraZenenca
-
11.4.1 AstraZenenca Company Details
-
11.4.2 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.4.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer
-
11.5.1 Pfizer Company Details
-
11.5.2 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.5.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Actavis
-
11.6.1 Actavis Company Details
-
11.6.2 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
11.6.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
12 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Preface Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Eluxadoline Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Alosetron Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Rifaximin Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Loperamide Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Diphenoxylate + Atropine Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Dicyclomine and Hyoscyamine Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Outlook to 2028
-
13.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
-
Figure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture
-
Table Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Preface Consumption and Growth Rate (2017-2022)
-
Figure Global Eluxadoline Consumption and Growth Rate (2017-2022)
-
Figure Global Alosetron Consumption and Growth Rate (2017-2022)
-
Figure Global Rifaximin Consumption and Growth Rate (2017-2022)
-
Figure Global Loperamide Consumption and Growth Rate (2017-2022)
-
Figure Global Diphenoxylate + Atropine Consumption and Growth Rate (2017-2022)
-
Figure Global Dicyclomine and Hyoscyamine Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Table North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Country (2017-2022)
-
Figure Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption and Growth Rate (2017-2022)
-
Table Salix Pharmaceuticals Ltd Company Details
-
Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Table Astellas Pharmaceuticals Company Details
-
Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Table AstraZenenca Company Details
-
Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Table Actavis Company Details
-
Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Main Business and Markets Served
-
Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
-
Figure Global Preface Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Eluxadoline Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alosetron Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rifaximin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Loperamide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diphenoxylate + Atropine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dicyclomine and Hyoscyamine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
